Project Grant HT94252310492
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$534K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New Zealand
Similar Awards
The Department of the Army Medical Command awarded a $1,126,472 project grant under the Military Medical Research and Development (CFDA 12.420) program to The University of Auckland in New Zealand. The purpose of the grant is to identify the earliest druggable targets for Parkinson's disease. The award has a performance period from September 1, 2024 to August 31, 2027. As a prominent international research institution, The University of Auckland has established a strong track record of...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The University of Washington was awarded a $1,810,550 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 through September 30, 2026 to investigate early chemodenervation of the detrusor muscle to preserve bladder compliance and function over the long term following spinal cord injury. The Military Medical Research and Development program supports basic,...
The U.S. Defense Health Agency has awarded a $367,622 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to St. Vincent's Institute of Medical Research, a foreign-owned non-profit organization based in Australia. The grant supports a 2-year research project focused on studying the reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer. The research aims to transform healthcare for military service members and the broader public...
The Department of Defense's Defense Health Agency awarded a $700,032 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, effective August 1, 2025 through July 31, 2029, will fund research to investigate "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in RCC." This research aims to transform healthcare for military service members, veterans, and the broader public by...
This Project Grant award of $2,056,250.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports research by The Trustees of Columbia University in the City of New York, Health Sciences Division, to target cervical epidural spinal cord stimulation for functional recovery. The project will run from September 1, 2024 to August 31, 2027. This award is part of the DHA's strategy to transform healthcare for military service members,...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The University of Queensland received a $1,120,707 project grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to develop a first-in-class calcium channel inhibitor for the treatment of advanced metastatic prostate cancers resistant to next-generation antiandrogen therapy. The award has a performance period from July 1, 2025, to June 30, 2028, and aims to transform healthcare for military service members, veterans, and the broader public...
The Defense Health Agency awarded a $3.755 million Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to investigate dual orexin antagonist treatment to prevent neurobehavioral sequelae of traumatic brain injury from April 1, 2023 to March 31, 2027. The Military Medical Research and Development program supports innovative medical research to improve warfighter health and transform public healthcare. Under this award,...
The Defense Health Agency awarded a $856,523 project grant to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will focus on the neurovascular and cognitive recovery from the spectrum of traumatic brain injuries through high-low...